Emboline has closed US$20 Million in growth capital, supporting its efforts to advance new technology for reducing stroke and ischaemic damage during structural heart procedures.
Emboline recently completed enrolment in the PROTECT H2H investigational device exemption (IDE) clinical trial, a prospective randomised study evaluating the Emboliner embolic protection system. The funding will support Emboline’s upcoming commercial launch activities and continued development of its embolic protection technology platform.
The Emboliner embolic protection system is designed to provide full cerebral and systemic embolic protection by capturing and removing embolic debris released during transcatheter heart procedures. Emboline also holds an extensive intellectual property portfolio related to aortic embolic protection technologies, including full-body embolic filtration and aortic deflection approaches.
Results from the completed IDE clinical study will be presented in a late-breaking clinical trial session at the American College of Cardiology (ACC) annual scientific session (28–30 March, New Orleans, USA).
“Emboline’s embolic filtering technology is designed with the goal of giving interventional cardiologists greater confidence when performing complex structural heart procedures while helping reduce the risk of stroke and other embolic complications,” said Rob Lake, senior managing director of Life Sciences at Trinity Capital, the alternative asset manager behind the investment. “We are pleased to support Emboline during this important stage as the company prepares to bring its technology to physicians and patients worldwide.”
“We are excited to partner with Trinity Capital at a pivotal moment for Emboline,” said Scott Russell, President and CEO of Emboline. “With the completion of our IDE clinical trial and regulatory submissions ahead, this financing positions us to prepare for commercial launch in the USA and Europe later this year. Our goal is to provide physicians with a comprehensive embolic protection solution that helps reduce stroke and ischemic injury during transcatheter procedures.”
With this financing, Emboline will advance preparations for the commercial introduction of the Emboliner embolic protection system while continuing development of additional technologies designed to reduce embolic risk during structural heart interventions.
